The effect of glucagon-like peptide 1 receptor agonists on patients with joint infections was a popular topic at the American ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

As the indications and demand for glucagon-like peptide-1 (GLP-1) agonist drugs continue to expand, the real-world GLP-1 research and data-driven insights from Prime Therapeutics LLC (Prime) help ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Glucagon-like peptide-1 receptor agonists such as Ozempic ... The Wall Street Journal reported March 10. Blockbuster GLP-1 medications like Ozempic and Wegovy are transforming patient care ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.